文献速递免疫规划妇幼与学校卫生卫生政策与健康促进

美国孕妇B族链球菌疫苗的成本效果分析

Cost-effectiveness of a potential group B streptococcal vaccine for pregnant women in the United States.
PubMed 文献 · Vaccine · 2017-09-23

研究用决策分析模型比较五种预防婴儿B族链球菌(GBS)疾病策略的成本效果,发现仅筛查加产时抗生素预防(IAP)相比无预防可预防46%早发型GBS,成本为每质量调整生命年(QALY)70,275美元(医疗视角)和51,249美元(社会视角,2013年美元)。五价疫苗覆盖率典型时,单独接种在效力接近90%前预防疾病不如筛查/IAP,但每QALY成本更低;疫苗效力≥70%时,接种联合对未接种妇女的IAP比筛查/IAP预防更多疾病且成本/QALY相近。

要点

  • 仅筛查/IAP相比无预防预防46%早发型GBS,成本每QALY 70,275美元(医疗)和51,249美元(社会,2013年美元)。
  • 五价疫苗单独接种在效力接近90%前预防疾病不如筛查/IAP,但每QALY成本更低。
  • 疫苗效力≥70%时,接种联合未接种妇女的IAP比筛查/IAP预防更多疾病,成本/QALY相近。

核心结论

  • 若五价疫苗足够有效,孕妇GBS免疫接种联合对未接种妇女的指示性IAP可能成为筛查/IAP的有吸引力替代方案。
  • 孕妇疫苗的覆盖率通常较低,是影响疫苗公共卫生效果的关键。

研究设计与样本

  • 研究使用决策分析模型,比较五种预防婴儿GBS疾病策略:无预防、现行推荐的筛查/IAP、孕妇GBS免疫接种、接种联合对未接种妇女的指示性IAP、接种联合所有妇女的筛查/IAP。
  • 模型假设五价疫苗覆盖血清型1a、1b、II、III和V,这些血清型几乎引起所有GBS疾病。

主要发现

  • 基础案例分析中,仅筛查/IAP相比无预防可预防46%的早发型GBS,成本为每QALY 70,275美元(医疗视角)和51,249美元(社会视角,2013年美元)。
  • 在美国孕妇疫苗典型覆盖率下,五价疫苗单独接种在效力接近90%前预防疾病不如筛查/IAP,但每QALY成本更低。
  • 疫苗效力≥70%时,孕妇免疫接种联合对未接种妇女的IAP比筛查/IAP预防更多疾病,且成本/QALY相近。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the U.S., intrapartum antibiotic prophylaxis (IAP) for pregnant women colonized with group B streptococcus (GBS) has reduced GBS disease in the first week of life (early-onset/EOGBS). Nonetheless, GBS remains a leading cause of neonatal sepsis, including 1000 late-onset (LOGBS) cases annually. A maternal vaccine under development could prevent EOGBS and LOGBS. METHODS: Using a decision-analytic model, we compared the public health impact, costs, and cost-effectiveness of five strategies to prevent GBS disease in infants: (1) no prevention; (2) currently recommended screening/IAP; (3) maternal GBS immunization; (4) maternal immunization with IAP when indicated for unimmunized women; (5) maternal immunization plus screening/IAP for all women. We modeled a pentavalent vaccine covering serotypes 1a, 1b, II, III, and V, which cause almost all GBS disease. RESULTS: In the base case, screening/IAP alone prevents 46% of EOGBS compared to no prevention, at a cost of $70,275 per quality-adjusted life-year (QALY) from a healthcare and $51,249/QALY from a societal perspective (2013 US$). At coverage rates typical of maternal vaccines in the U.S., a pentavalent vaccine alone would not prevent as much disease as screening/IAP until its efficacy approached 90%, but would cost less per QALY. At vaccine efficacy of ≥70%, maternal immunization together with IAP for unimmunized women would prevent more disease than screening/IAP, at a similar cost/QALY. CONCLUSIONS: GBS maternal immunization, with IAP as indicated for unvaccinated women, could be an attractive alternative to screening/IAP if a pentavalent vaccine is sufficiently effective. Coverage, typically low for maternal vaccines, is key to the vaccine's public health impact.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Kim SY, Nguyen C, Russell LB, et al. Cost-effectiveness of a potential group B streptococcal vaccine for pregnant women in the United States. Vaccine. 2017. PMID: 28951085. doi:10.1016/j.vaccine.2017.08.085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。